United Health Products, Inc. (OTC Pink: UEEC) is engaged within the research, development, and marketing of HemoStyp, proprietary patent hemostatic gauze for wound care and healthcare treatment. Shares of the medical products developer are rallying 25.24%, through afternoon trading on Tuesday, December 12, 2017. Over the past month, United Health Products, Inc. has seen average daily volume of 88,591 shares. However, volume of 857,736 shares or dollar volume of $428,868, has already exchanged hands on the day.
Shares of United Health Products, Inc. are rallying today, after the company announced that it is applying to have its HemoStyp medical product classified as a Class III medical device with Australia’s Therapeutics Goods Administration (TGA). The company says it could be able to utilize HemoStyp within Australia within the next 30 days. Here is the press release detailing of the regulation application:
United Health Products, Inc. Press Release:
HENDERSON, Nev., Dec. 12, 2017 (GLOBE NEWSWIRE) — United Health Products, Inc. (UHP) (OTC:UEEC), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced it is applying to have HemoStyp designated as a Class III medical device with Australia’s Therapeutics Goods Administration (TGA, counterpart to the U.S. FDA). Similar to the US FDA Class III application, this will allow for internal surgical use. The company’s Australian TGA consultants believe that UHP has the requisite test data and documentation to obtain rapid approval in Australia, and that HemoStyp® could obtain approval for use in the Australian market within 30 days.
About TGA The Therapeutic Goods Administration (TGA) is Australia’s regulatory authority for therapeutic goods. We carry out a range of assessment and monitoring activities to ensure therapeutic goods available in Australia are of an acceptable standard with the aim of ensuring that the Australian community has access, within a reasonable time, to therapeutic advances. https://www.tga.gov.au/about-tga
About United Health Products, Inc.
United Health Products, Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UHP is focused on identifying new markets and applications for its products, and expanding its current markets.
For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
